整合盒(iBox)预后系统在非洲裔美国肾移植受者中的表现
该多中心研究纳入3866例北美肾移植受者(非洲裔1040例,占27%),评估iBox预测移植肾丢失的效能。非洲裔与非非洲裔受者的区分度(C指数0.80 vs 0.83,P=0.07)和观察/期望比(1.08 vs 0.99,P=0.28)相似,且iBox评分与种族无显著交互作用(P=0.24),支持iBox在该人群中的稳健性。
要点
- iBox在非洲裔与非非洲裔肾移植受者中区分度相似(C指数0.80 vs 0.83,P=0.07)。
- 观察/期望比在两组间无显著差异(1.08 vs 0.99,P=0.28)。
- iBox评分与种族无显著交互作用(P=0.24),支持其稳健性。
核心结论
- iBox预后系统在非洲裔和非非洲裔肾移植受者中均显示出准确的区分度、整体拟合和临床实用性,支持其在该人群中的稳健性。
研究设计与样本
- 多中心研究纳入3866例北美肾移植受者,其中1040例(27%)为非洲裔美国人,评估iBox预测移植肾丢失的效能。
主要发现
- 非洲裔与非非洲裔受者的C指数分别为0.80(95%CI 0.77-0.83)和0.83(95%CI 0.81-0.85),P=0.07。
- 观察/期望比分别为1.08(95%CI 0.95-1.23)和0.99(95%CI 0.88-1.10),P=0.28。
- 按移植中心分层的多变量分析中,iBox评分与种族无显著交互作用(交互项P=0.24)。
- 无论使用何种eGFR估算公式(肾脏受者特异性、CKD-EPI或MDRD),亚组间结果一致,但校准在不同公式间有变异。
临床怎么用
- iBox可用于非洲裔美国肾移植受者的长期移植肾丢失风险预测,支持其在该人群中的临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: The integrative box showed accurate discrimination, overall fit, and clinical utility in 3866 kidney transplant recipients from North America. Predictive performance was maintained in African American and non-African American kidney transplant recipients. These results support the robustness of the integrative box as a risk prediction tool. BACKGROUND: The integrative box (iBox) is a validated prognostication system that predicts long-term death-censored graft loss in kidney transplant recipients, but its performance in the specific population of African American recipients has not been fully studied. METHODS: We conducted a multicenter study including 3866 kidney transplant recipients from North America, of whom 1040 (27%) were African American, to assess the impact of race on the iBox's performance in predicting graft loss. Discrimination, calibration, overall fit, and clinical utility were evaluated in the whole cohort and in African American and non-African American recipients. RESULTS: Performance metrics for the prediction of graft loss were similar in both subgroups in discrimination (C-index 0.80 [95% confidence interval (CI), 0.77 to 0.83] in African American recipients and 0.83 [95% CI, 0.81 to 0.85] in non-African American recipients, P = 0.07) and observed/expected ratios (1.08 [95% CI, 0.95 to 1.23] and 0.99 [95% CI, 0.88 to 1.10], respectively, P = 0.28). No significant interaction between iBox score values and race was found in multivariable analysis stratified by transplant center ( P = 0.24 for the interaction term). The results were consistent between the subgroups regardless of the equation used to estimate eGFR (Kidney Recipient Specific, CKD-Epidemiology Collaboration, or Modification of Diet in Renal Disease), but with variations in calibration across equations. CONCLUSIONS: The iBox prognostication system showed accurate discrimination, overall fit, and clinical utility up to 7 years after risk evaluation in African American and non-African American kidney transplant recipients, supporting its robustness in this population. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT03474003 .
引用
- Truchot A, Lombardi Y, Raynaud M, et al. Performance of the Integrative Box (iBox) Prognostication System in African American Kidney Transplant Recipients. J Am Soc Nephrol. 2026. PMID: 42720987. doi:10.1681/ASN.0000001247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。